Wenqing Wei. Clinical predictive values of biomarker levels in non-small cell lung cancer. Oncol Transl Med, 2017, 3: 245-248. |
Clinical predictive values of biomarker levels in non-small cell lung cancer |
Received:July 18, 2017 Revised:January 21, 2018 |
View Full Text View/Add Comment Download reader |
KeyWord:non-small cell lung cancer; PD-1; IL-17; IL-21 |
Author Name | Affiliation | E-mail | Wenqing Wei | Army General Hospital, Beijing, 100700, China | wqwei2000@qq.com |
|
Hits: 8158 |
Download times: 8672 |
Abstract: |
Objective To evaluate the predictive value of serum levels of PD-1, IL-17, and IL-21 in patients with nonsmall
cell lung cancer.
Methods Serum levels of PD-1, IL-17, and IL-21 were analyzed by ELISA in 45 patients with non-small
cell lung cancer (NSCLC) and 30 healthy individuals.
Results Serum PD-1, IL-17, and IL-21 levels were significantly different between preoperative patients
with NSCLC and the control group (P < 0.01), while there was no significant differences between the
postoperative patients and the control group (P > 0.05). Comparison of serum PD-1, IL-17, and IL-21 levels
of patients with NSCLC before and after the operation revealed a decrease in PD-1 and IL-17 levels and an
increase in IL-21 levels. The serum levels of PD-1 and IL-17 were higher in patients with advanced staged
disease than in those with early stage cancer (P < 0.05), while IL-21 levels were lower at the advanced
stages (P < 0.05).
Conclusion In patients with NSCLC, serum levels of PD-1, IL-17, and IL-21 changed considering the
surgical operation and the course of the disease. Screening these biomarker levels might provide a helpful
index for treatment and prognosis. |
Close |
|
|
|